Investors Encouraged to Reach Out Regarding Geron Claims
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson is actively inviting investors who have suffered significant losses exceeding $100,000 in Geron to connect with him directly. This is a pivotal moment for affected parties to discuss their available legal options. If this applies to you, please reach out to Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
Geron Corporation Under Investigation
As a leading national securities law firm, Faruqi & Faruqi, LLP is conducting an in-depth investigation into potential claims against Geron Corporation, publicly traded as NASDAQ: GERN. The firm reminds investors of the approaching deadline to seek the role of lead plaintiff in a federal securities class action that has been initiated against Geron.
Key Events and Allegations
Recent developments have raised eyebrows, especially following Geron’s announcement regarding their financial results. The report indicated a plateau in Rytelo’s growth, further exacerbated by various factors that included competition and awareness of the drug. These findings have prompted concerns regarding the management's previous reassurances about the drug's market potential. Investors who feel affected should consider their legal standings without delay.
The Decline in Geron Stock
Significant investor concern arose when Geron disclosed its fourth-quarter financial results, indicating a marked decline in Rytelo's growth due to multiple market pressures. The drop from a closing share price of $2.37 on February 25, 2025, to $1.61 the following day represents a sharp decline of approximately 32.07%, highlighting the urgency for investors to assess their positions.
What Affected Investors Should Know
The court will appoint a lead plaintiff from among the investors with the largest financial interest who can adequately represent the class. Prospective lead plaintiffs may approach the court through their chosen legal counsel, but the decision to serve in this capacity is not mandatory for recovery options. Any affected party may still receive a share of the recovery, regardless of participation in leading the case.
Invitation for Contact
Faruqi & Faruqi, LLP is reaching out to anyone with valuable information related to Geron’s practices, including former employees, whistleblowers, or shareholders. Open lines of communication can bolster the ongoing investigation.
Taking Action Now
For further details on the Geron class action, visit www.faruqilaw.com/GERN or engage directly with Faruqi & Faruqi partner Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310). Taking action now can make a significant difference in the outcomes for affected investors.
Frequently Asked Questions
What is the main purpose of this announcement?
This announcement aims to inform investors about potential legal actions related to losses incurred with Geron Corporation and encourages them to contact Faruqi & Faruqi for assistance.
How can I participate in the class action?
Investors can participate by contacting Faruqi & Faruqi to discuss their situation and potentially serve as lead plaintiffs in the class action.
What are the allegations against Geron Corporation?
The allegations suggest that Geron and its executives violated federal securities laws by making misleading statements regarding the company's market performance and product potential.
What should I do if I have information about Geron?
If you have relevant information about Geron's actions or the impact on investors, it is encouraged to contact Faruqi & Faruqi for investigation support.
What timeline should investors be aware of?
Investors should be mindful of the approaching deadline to seek the lead plaintiff role, along with ongoing updates related to the case.
